The University of Southampton
University of Southampton Institutional Repository

High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate

High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI >14, and only in 35% of AML cases with a bcl-2 MFI >14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (>14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.
AML, bcl-2, CR, CD34, MFI
0887-6924
2075-2078
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Rondelli, D.
e7380678-2518-42cb-ae10-d4ef8b900417
Ventura, M. A.
3214389e-be33-4bcd-889d-624370098eae
Fiacchini, M.
32fca2b4-7c75-41e1-a707-a4973240bfa8
Visani, G.
a0b74eed-6389-4cc6-b2c5-9f7e5e160653
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Tura, S.
eed48885-b319-4446-a488-c3193a83c2bc
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Rondelli, D.
e7380678-2518-42cb-ae10-d4ef8b900417
Ventura, M. A.
3214389e-be33-4bcd-889d-624370098eae
Fiacchini, M.
32fca2b4-7c75-41e1-a707-a4973240bfa8
Visani, G.
a0b74eed-6389-4cc6-b2c5-9f7e5e160653
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Tura, S.
eed48885-b319-4446-a488-c3193a83c2bc

Lauria, F., Raspadori, D., Rondelli, D., Ventura, M. A., Fiacchini, M., Visani, G., Forconi, Francesco and Tura, S. (1997) High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia, 11 (12), 2075-2078. (PMID:9447823)

Record type: Article

Abstract

Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI >14, and only in 35% of AML cases with a bcl-2 MFI >14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (>14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.

This record has no associated files available for download.

More information

Published date: December 1997
Keywords: AML, bcl-2, CR, CD34, MFI
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 358192
URI: http://eprints.soton.ac.uk/id/eprint/358192
ISSN: 0887-6924
PURE UUID: 6a6f81ae-bc5d-48f1-a8d3-8b55a2572fd3
ORCID for Francesco Forconi: ORCID iD orcid.org/0000-0002-2211-1831

Catalogue record

Date deposited: 23 Oct 2013 10:50
Last modified: 24 Nov 2022 02:44

Export record

Contributors

Author: F. Lauria
Author: D. Raspadori
Author: D. Rondelli
Author: M. A. Ventura
Author: M. Fiacchini
Author: G. Visani
Author: S. Tura

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×